These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 2058454

  • 1. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.
    Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rüde E, Thoenes GH, Küchle CC, Schorlemmer HU, Bremer E.
    Agents Actions; 1991 Jan; 32(1-2):10-21. PubMed ID: 2058454
    [Abstract] [Full Text] [Related]

  • 2. Effects of leflunomide on immune responses and models of inflammation.
    Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R.
    Springer Semin Immunopathol; 1993 Jan; 14(4):381-94. PubMed ID: 8322168
    [No Abstract] [Full Text] [Related]

  • 3. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
    Herrmann ML, Schleyerbach R, Kirschbaum BJ.
    Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
    [Abstract] [Full Text] [Related]

  • 4. Leflunomide and malononitrilamides.
    Silva Júnior HT, Morris RE.
    Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
    [Abstract] [Full Text] [Related]

  • 5. Leflunomide prevents the development of experimentally induced myasthenia gravis.
    Vidic-Dankovic B, Kosec D, Damjanovic M, Apostolski S, Isakovic K, Bartlett RR.
    Int J Immunopharmacol; 1995 Apr; 17(4):273-81. PubMed ID: 7672879
    [Abstract] [Full Text] [Related]

  • 6. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats.
    Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R.
    Int J Immunopharmacol; 1989 Apr; 11(8):921-9. PubMed ID: 2613396
    [Abstract] [Full Text] [Related]

  • 7. Leflunomide. Arava, HWA 486, SU 101.
    Drugs R D; 1999 Jan; 1(1):87-91. PubMed ID: 10565997
    [No Abstract] [Full Text] [Related]

  • 8. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
    Bartlett RR, Brendel S, Zielinski T, Schorlemmer HU.
    Transplant Proc; 1996 Dec; 28(6):3074-8. PubMed ID: 8962190
    [No Abstract] [Full Text] [Related]

  • 9. [Leflunomide--a new drug for pharmacological immunomodulation].
    Wozel G, Pfeiffer C.
    Hautarzt; 2002 May; 53(5):309-15. PubMed ID: 12063741
    [Abstract] [Full Text] [Related]

  • 10. The effects of leflunomide and cyclosporin A on rejection of cardiac allografts in the rat.
    Ostraat O, Qi ZQ, Tufveson G, Hedlund G, Ekberg H.
    Scand J Immunol; 1998 Mar; 47(3):236-42. PubMed ID: 9519862
    [Abstract] [Full Text] [Related]

  • 11. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
    Sanders S, Harisdangkul V.
    Am J Med Sci; 2002 Apr; 323(4):190-3. PubMed ID: 12003373
    [Abstract] [Full Text] [Related]

  • 12. Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide.
    Mrowka C, Thoenes GH, Langer KH, Bartlett RR.
    Ann Hematol; 1994 Apr; 68(4):195-9. PubMed ID: 8003561
    [Abstract] [Full Text] [Related]

  • 13. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine.
    Williams JW, Xiao F, Foster P, Clardy C, McChesney L, Sankary H, Chong AS.
    Transplantation; 1994 Apr 27; 57(8):1223-31. PubMed ID: 8178350
    [Abstract] [Full Text] [Related]

  • 14. The broadening use of leflunomide in clinical practice.
    Kiely PD.
    Hosp Med; 2004 Dec 27; 65(12):735-9. PubMed ID: 15624449
    [Abstract] [Full Text] [Related]

  • 15. Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes.
    Stosic-Grujicic S, Dimitrijevic M, Bartlett R.
    Clin Exp Immunol; 1999 Jul 27; 117(1):44-50. PubMed ID: 10403914
    [Abstract] [Full Text] [Related]

  • 16. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.
    Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT.
    J Pharmacol Exp Ther; 1995 Jan 27; 272(1):460-8. PubMed ID: 7529314
    [Abstract] [Full Text] [Related]

  • 17. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD, Brooks JB.
    Expert Rev Clin Pharmacol; 2015 May 27; 8(3):315-20. PubMed ID: 25712857
    [Abstract] [Full Text] [Related]

  • 18. Leflunomide controls rejection in hamster to rat cardiac xenografts.
    Xiao F, Chong AS, Foster P, Sankary H, McChesney L, Koukoulis G, Yang J, Frieders D, Williams JW.
    Transplantation; 1994 Oct 15; 58(7):828-34. PubMed ID: 7940718
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of leflunomide in active rheumatoid arthritis.
    Smolen JS, Emery P.
    Rheumatology (Oxford); 2000 Jun 15; 39 Suppl 1():48-56. PubMed ID: 11001380
    [Abstract] [Full Text] [Related]

  • 20. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases.
    Mangold U, Dax CI, Saar K, Schwab W, Kirschbaum B, Müllner S.
    Eur J Biochem; 1999 Dec 15; 266(3):1184-91. PubMed ID: 10583416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.